Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Alexion Pharm Inc (ALXN)

Alexion Pharm Inc (ALXN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,636,188
  • Shares Outstanding, K 219,173
  • Annual Sales, $ 4,991 M
  • Annual Income, $ 2,404 M
  • 60-Month Beta 1.39
  • Price/Sales 4.56
  • Price/Cash Flow 8.89
  • Price/Book 2.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 2.18
  • Number of Estimates 10
  • High Estimate 2.47
  • Low Estimate 1.92
  • Prior Year 2.55
  • Growth Rate Est. (year over year) -14.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
100.83 +2.43%
on 07/24/20
113.00 -8.60%
on 07/08/20
-9.18 (-8.16%)
since 07/07/20
3-Month
96.69 +6.81%
on 05/08/20
121.50 -15.00%
on 06/01/20
+6.36 (+6.56%)
since 05/07/20
52-Week
72.67 +42.12%
on 03/16/20
125.52 -17.72%
on 08/22/19
-5.63 (-5.17%)
since 08/07/19

Most Recent Stories

More News
Alexion Announces Appointment of First Chief Diversity Officer

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the appointment of Uzair Qadeer as the company's first Chief Diversity Officer. In this new role, Mr. Qadeer will be responsible for shaping...

ALXN : 103.28 (-0.60%)
4 S&P 500 Stocks with HEAVY Insider Buying

Stocks with strong insider buying can be a good indicator for future price appreciation. Here are four stocks in the S&P 500 with the highest recent positive insider transactions: Sysco Corporation (SYY),...

SYY : 57.80 (+2.48%)
ALXN : 103.28 (-0.60%)
TDG : 475.39 (+0.70%)
NWL : 17.15 (+1.96%)
Orphan Drugs Market to Reach USD 340.84 Billion by 2027; Increasing Incidence of Life-threatening Diseases will Bode well for Market Growth, says Fortune Business Insights(TM)

The global orphan drugs market size is projected to reach USD 340.84 billion by the end of 2027. Increasing number of regulatory approvals will have a positive impact on the growth of the overall market...

ALXN : 103.28 (-0.60%)
BAYRY : 16.4610 (-0.96%)
BMY : 61.02 (-0.51%)
GSK : 40.79 (-0.44%)
NVO : 64.64 (+1.49%)
Alexion (ALXN) Beats on Q2 Earnings & Sales, Ups '20 Guidance

Alexion (ALXN) beats on earnings and sales in the second quarter of 2020.

ALXN : 103.28 (-0.60%)
BMRN : 118.67 (-0.82%)
EBS : 130.66 (+2.91%)
APLT : 27.12 (+0.89%)
Alexion Pharmaceuticals (ALXN) Beats Q2 Earnings and Revenue Estimates

Alexion (ALXN) delivered earnings and revenue surprises of 21.96% and 14.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

ALXN : 103.28 (-0.60%)
Alexion: 2Q Earnings Snapshot

BOSTON (AP) _ Alexion Pharmaceuticals Inc. (ALXN) on Thursday reported a second-quarter loss of $1.07 billion, after reporting a profit in the same period a year earlier.

ALXN : 103.28 (-0.60%)
Big Drug Stock Q2 Earnings on Jul 30: LLY, GILD, VRTX & More

Let us take a look at five big drug/biotech companies, GILD, LLY, VRTX, ALXN, and AZN, gearing up for their earnings release.

ALXN : 103.28 (-0.60%)
AZN : 55.41 (-1.42%)
GILD : 69.35 (+0.78%)
LLY : 152.93 (+0.03%)
VRTX : 272.99 (-0.13%)
Sorrento (SRNE) to Report Q2 Earnings: What's in the Cards?

Sorrento (SRNE) will provide updates on its drugs and revenues when it releases second-quarter 2020 results.

ALXN : 103.28 (-0.60%)
ACAD : 42.73 (-2.06%)
BLUE : 63.48 (-0.56%)
SRNE : 14.42 (+5.95%)
Nabriva (NBRV) to Report Q2 Earnings: What's in the Cards?

Nabriva (NBRV) will provide updates on its drugs and revenues when it releases second-quarter 2020 results.

ALXN : 103.28 (-0.60%)
ACAD : 42.73 (-2.06%)
BLUE : 63.48 (-0.56%)
NBRV : 0.7349 (-9.27%)
Why Earnings Season Could Be Great for Alexion (ALXN)

Alexion (ALXN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ALXN : 103.28 (-0.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade ALXN with:

Business Summary

Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes...

See More

Key Turning Points

2nd Resistance Point 105.10
1st Resistance Point 104.19
Last Price 103.28
1st Support Level 102.34
2nd Support Level 101.40

See More

52-Week High 125.52
Fibonacci 61.8% 105.33
Last Price 103.28
Fibonacci 50% 99.10
Fibonacci 38.2% 92.86
52-Week Low 72.67

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar